Harmony Biosciences Inc. (HRMY)
32.54
0.12 (0.37%)
At close: Apr 02, 2025, 3:59 PM
31.78
-2.32%
After-hours: Apr 02, 2025, 06:29 PM EDT
Company Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States.
Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.
Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Harmony Biosciences Inc.
| Country | United States |
| IPO Date | Aug 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 268 |
| CEO | Dr. Jeffrey M. Dayno M.D. |
Contact Details
Address: 630 West Germantown Pike Plymouth Meeting, Pennsylvania United States | |
| Website | https://www.harmonybiosciences.com |
Stock Details
| Ticker Symbol | HRMY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001802665 |
| CUSIP Number | 413197104 |
| ISIN Number | US4131971040 |
| Employer ID | 82-2279923 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey M. Dayno M.D. | President, Chief Executive Officer & Director |
| Sandip S. Kapadia CPA, M.B.A. | Executive Vice President, Chief Administrative Officer & Chief Financial Officer |
| Andrew Serafin J.D., M.B.A. | Executive Vice President & Chief Strategy Officer |
| Brennan Doyle | Vice President & Head of Investor Relations |
| Christian Ulrich J.D. | General Counsel & Corporate Secretary |
| David Bradshaw | Head of Technical Operations |
| Dr. Kumar Budur M.D., M.S. | Executive Vice President and Chief Medical & Scientific Officer |
| Jeffrey Dierks M.B.A. | Executive Vice President & Chief Commercial Officer |
| Jeffrey S. Aronin | Founder & Non-Executive Chairman |
| Tricia Glover | Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 01, 2025 | 4 | Filing |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 05, 2025 | 4 | Filing |
| Feb 25, 2025 | S-8 | Filing |
| Feb 25, 2025 | S-3ASR | Automatic shelf registration statement of securiti... |
| Feb 25, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 05, 2025 | SCHEDULE 13G/A | [Amend] Filing |